Cytocom, Inc. Announces Plan to Adopt New Corporate Name “Statera BioPharma, Inc.”20210831113333
Cytocom, Inc. Announces Plan to Adopt New Corporate Name “Statera BioPharma, Inc.”
August 31, 20210 comments
New Corporate Name and Updated Stock Ticker Symbol to Showcase Company’s Post-Merger Transformation and Focus on Restoring Immune Health FORT CO...
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast20210816143628
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
August 16, 20210 comments
Audio archive for the event may be accessed from the “Investors” section of the Cytocom website FORT COLLINS, Colo., Aug. 16, 2021 –...
Cytocom, Inc. Reports Second Quarter 2021 Financial Results20210816113131
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
August 16, 20210 comments
-All-stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, Inc. common stock trading on Nasdaq as ...
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast20210816103400
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
August 16, 20210 comments
Audio archive for the event may be accessed from the “Investors” section of the Cytocom website FORT COLLINS, Colo., Aug. 16, 2021 –...
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement20210812200732
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
August 12, 20210 comments
Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious diseases and applications to clinical-stage therapies Resea...
Cytocom, Inc. Announces Participation at Liberty University’s Empowering the Kingdom Through Business Conference20210811113139
Cytocom, Inc. Announces Participation at Liberty University’s Empowering the Kingdom Through Business Conference
August 11, 20210 comments
Mike K. Handley, President and CEO, will participate as featured panelist FORT COLLINS, Colo., Aug. 11, 2021 — Cytocom, Inc. (NASDAQ: CBLI)...
Cytocom, Inc. to Report Second Quarter 2021 Financial Results20210810113148
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
August 10, 20210 comments
Executive Management to Host Conference Call on Monday, August 16th at 8:30 a.m. ET FORT COLLINS, Colo., Aug. 10, 2021 – Cytocom, Inc. ...
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn’s Disease, Hematology, Pancreatic Cancer and COVID-1920210809073000
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn’s Disease, Hematology, Pancreatic Cancer and COVID-19
August 9, 20210 comments
Patient enrollment in Phase 3 pediatric Crohn’s disease trial expected to initiate by year-end 2021; End-of-Phase 2 meeting successfully complet...
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger20210706132314
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
July 6, 20210 comments
FORT COLLINS, Colo. and BUFFALO, N.Y., July 6, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company de...
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC20210618103429
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
June 18, 20210 comments
FORT COLLINS, Colo. and BUFFALO, N.Y., June 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company d...